Address Hotels and Resorts Announces the Opening of Address Jabal Omar Makkah Unveiling a Spiritual Haven in the Heart of Makkah
12.7.2023 09:00:00 EEST | Business Wire | Press release
Address Hotels and Resorts is thrilled to announce the opening of its latest architectural and hospitality masterpiece, Address Jabal Omar Makkah, in the holy city of Makkah, Saudi Arabia. Nestled in the iconic Jabal Omar development, this landmark property offers a truly unforgettable experience for pilgrims and travellers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711493267/en/
Panoramic Kaaba view from Address Jabal Omar Makkah (Photo: AETOSWire)
The largest hotel within the Address Hotels and Resorts portfolio, Address Jabal Omar Makkah boasts an impressive 1,484 rooms and suites. With its striking architectural design, a seamless fusion of ancient Arabian charm and contemporary opulence, the hotel is the tallest building in Jabal Omar and is a breathtaking sight.
One standout feature of Address Jabal Omar Makkah is its proximity to the sacred Holy Kaaba and Al Masjid Al Haram, along with the Makkah Museum, Masjid Al Jinn, Jannat al-Mu'alla Cemetery, and the iconic Abraj Al Bait Towers. Designed by the world-renowned architects Foster & Partners, the towers of Address Jabal Omar Makkah span over 5,000 sqm and the development includes a commercial area featuring a diverse range of shops, showcasing local, regional, and international brands.
Address Jabal Omar Makkah offers a range of exquisitely designed accommodations to suit every traveller’s needs. From luxurious Deluxe Rooms, which provide splendid views of the Holy Kaaba or the Holy City, to indulgent Suites and the magnificent three-bedroom Presidential Suite and four-bedroom Penthouse, guests can immerse themselves in comfort and elegance.
With four restaurants, two lobby lounges, and two club lounges, guests can also savour a wide range of delectable cuisines. The hotel's signature dining venue offers traditional Hejazi cuisine and other Saudi Arabian specialties, where live cooking stations showcase international flavours alongside time-honoured delicacies.
The spa and wellness offerings, including the first-ever Foot Spa by Address Hotels and Resorts, at the hotel are designed to provide guests with a truly holistic experience. With a complimentary Fitness Centre, equipped with the latest Technogym equipment on hand as well, guests can maintain their well-being during their stay.
Address Jabal Omar Makkah is also a premier destination for conferences and events. Whatever the occasion, the hotel’s unparalleled settings and services help create cherished moments. The property's multifunctional meeting spaces are designed to cater to events of any scale. The hotel's creative chefs curate menus tailored to individual preferences, ensuring a flawless and memorable event.
Mark Kirby, Head of Emaar Hospitality, said, “We are delighted to announce the opening of Address Jabal Omar Makkah. Its prime location makes it the preferred choice for those seeking to deepen their spiritual connection. With spacious rooms and suites, multiple dining options, and state-of-the-art prayer facilities, the hotel offers all the amenities necessary for a meaningful and unforgettable pilgrimage experience. Whether guests are here for Hajj, Umrah, or to enhance their spiritual connection, Address Jabal Omar Makkah Hotel is the optimal starting point for their journey.”
The hotel is proud to be a part of Saudi Arabia's Vision 2030, which aims to transform the country's tourism landscape.
To reserve with a 15% discount, click the link, visit our website, or email stayatmakkah@addresshotels.com or call +966-0125531444.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711493267/en/
Contact information
Mohammad Jamil
Mohammad.j@addresshotels.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom